Clinical Trial Update: Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG [Phase 2]

View source ↗

Summary

A Phase 2 platform trial is comparing Teplizumab with anti-thymocyte globulin (ATG) to delay progression to Stage 3 Type 1 Diabetes; the study is not yet recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Teplizumab (Teplizumab)
• anti-thymocyte globulin (antithymocyte globulin)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Type 1 Diabetes Mellitus | Phase 2 | Status: NOT_YET_RECRUITING